Outset Medical, Inc. (NASDAQ:OM) Receives $10.00 Consensus Price Target from Brokerages

Shares of Outset Medical, Inc. (NASDAQ:OM) have earned a consensus rating of “Hold” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $10.00.

Several brokerages have recently issued reports on OM. TD Cowen reiterated a “buy” rating on shares of Outset Medical in a research report on Friday, May 8th. Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research note on Wednesday, June 24th.

Insiders Place Their Bets

In other Outset Medical news, CFO Renee Gaeta sold 17,672 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total value of $87,299.68. Following the completion of the sale, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at approximately $561,939.82. This represents a 13.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 25,337 shares of company stock valued at $115,660. 2.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Outset Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in Outset Medical by 662.8% during the second quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock valued at $162,000 after purchasing an additional 7,344 shares during the last quarter. Legal & General Group Plc acquired a new position in Outset Medical in the second quarter worth approximately $34,000. Rhumbline Advisers acquired a new position in Outset Medical in the second quarter worth approximately $499,000. New York State Common Retirement Fund acquired a new position in Outset Medical in the second quarter worth approximately $108,000. Finally, Quantbot Technologies LP bought a new position in shares of Outset Medical in the second quarter valued at $152,000.

Outset Medical Trading Up 1.5%

Outset Medical stock opened at $4.12 on Friday. Outset Medical has a 12-month low of $3.00 and a 12-month high of $19.60. The company has a debt-to-equity ratio of 0.87, a current ratio of 6.29 and a quick ratio of 4.97. The stock has a market capitalization of $76.38 million, a PE ratio of -0.99 and a beta of 1.95. The firm has a 50 day simple moving average of $4.48 and a 200-day simple moving average of $4.27.

Outset Medical (NASDAQ:OM) last announced its earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.04). The firm had revenue of $27.86 million for the quarter, compared to the consensus estimate of $28.90 million. Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%. As a group, equities research analysts expect that Outset Medical will post -3.82 EPS for the current fiscal year.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.